MedPath

The Efficacy of SPSIPB on Postoperative Pain in Patients Undergoing Reduction Mammoplasty Surgery: Case Series

Not Applicable
Completed
Conditions
Post Operative Pain
Interventions
Other: Serratus posterior superior intercostal plane block (SPSIPB)
Registration Number
NCT05901116
Lead Sponsor
Cumhuriyet University
Brief Summary

The aim of this study is to investigate the postoperative analgesic efficacy of SPSIPB and its effect on opioid consumption in patients undergoing reduction mammoplasty.

Detailed Description

Ten patients had serratus posterior superior intercostal plane block (SPSIPB) as the intervention. Patients had SPSIPB with 0.25% bupivacaine (total volume of 30 ml) before the surgery in operating room. Numerical rating scale (NRS) was used to assess postoperative pain on 1st, 6th, 12th and 24th hour after the surgery. Total tramadol consumption was calculated by using patient-controlled analgesia (PCA) device. Patient satisfaction was assessed by using quality of recovery-15 (QoR15) scale. Paracetamol was planned as resque analgesic drug (maximum dose: 3 gr/day).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
10
Inclusion Criteria
  • Adult patients older than 18 years of age who underwent reduction mammoplasty under general anesthesia and are American Society of Anesthesiologists (ASA) I-II-III according to the ASA risk classification.
Exclusion Criteria
  • Patients who did not give consent,
  • patients with coagulopathy,
  • patients with signs of infection at the block application site,
  • patients using anticoagulants,
  • patients with local anesthetic drug allergies,
  • patients with unstable hemodynamics,
  • patients who could not cooperate during postoperative pain assessment

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
SPSIPBSerratus posterior superior intercostal plane block (SPSIPB)SPSIPB is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle. Tramadol (intravenous analgesic drug) at a concentration of 4 mg per 1 ml was administered with patient-controlled analgesia (PCA) device (max dose: 400 mg /day)
Primary Outcome Measures
NameTimeMethod
Numerical rating scale (NRS) scoresPostoperative 24 hours

Numerical rating scale was used for pain assessment. The scores of the numerical rating scale changes between 0 to 10 points. 10 points mean "the most severe pain that the patient ever had". 0 point means "there is no pain." Higher scores mean worse outcome.

Total Tramadol consumptionPostoperative 24 hours

Postoperative analgesic (tramadol) need was measured by using patient-controlled analgesia (PCA) device.

Secondary Outcome Measures
NameTimeMethod
Quality of Recovery scoresPostoperative 24 hours

Quality of recovery-15 (QoR15) scale was used for the assessment of patients satisfaction. The scores of QoR15 changes between 0 to 150 points. 0 point means "there is no satisfaction." Higher scores mean indicating a good quality of recovery and better outcome.

Resque analgesic needPostoperative 24 hours

Total paracetamol need was recorded as "milligram" in unit despite of tramadol administration.

Trial Locations

Locations (1)

Sivas Cumhuriyet University

🇹🇷

Sivas, Turkey

© Copyright 2025. All Rights Reserved by MedPath